Dr. Reddy's Challenges TONMYA Patents with Paragraph IV ANDA Filing
TNXP is trading near its 52-week low of $8.69 (2.8% above the low).
Summary
Dr. Reddy's filed a Paragraph IV ANDA challenging all four patents protecting TONMYA, Tonix's lead commercial drug. Tonix must sue within 45 days to trigger a 30-month stay of generic approval.
Key Events · Legal and Risk Events · TNXP
-
Paragraph IV ANDA Filed Against TONMYA
Dr. Reddy's Laboratories filed an ANDA with a Paragraph IV certification for a generic version of TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg, challenging U.S. Patent Nos. 9636408, 9956188, 10117936, and 10864175.
-
45-Day Window to File Infringement Suit
Tonix received the notice on October 1, 2026, and has 45 days to file a patent infringement lawsuit. Filing within that window automatically stays FDA approval of the ANDA for up to 30 months.
-
Threat to Lead Revenue Driver
TONMYA generated $11 million in Q2 2026 net sales, a 197% sequential increase, and is Tonix's primary commercial product. Generic competition could materially reduce this revenue.
-
Litigation Costs Add to Cash Pressure
Tonix's cash runway extends only into early Q2 2027. Patent litigation costs and management attention add further strain to an already constrained balance sheet.
Analysis · TNXP · Life Sciences
A Paragraph IV ANDA filing by Dr. Reddy's Laboratories seeks FDA approval for a generic version of TONMYA, Tonix's only commercial product, and challenges all four Orange Book-listed patents. TONMYA generated $11 million in Q2 2026 net sales and is the company's primary revenue driver. A successful generic challenge could eliminate most of that revenue. Tonix has 45 days to sue for patent infringement, which would trigger an automatic 30-month stay of FDA approval. The company's cash runway only extends into early Q2 2027, so the cost and distraction of patent litigation adds pressure to an already constrained balance sheet.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNXP was trading at $8.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $152.8M. The 52-week trading range was $8.69 to $25.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.